← Back to Search

Hormone Therapy

Oxytocin for Labor Complications (ROSSoL Trial)

N/A
Recruiting
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not have
Not on oxytocin at the time of complete cervical dilation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during admission for delivery
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether oxytocin can help during the second stage of labor.

Who is the study for?
This trial is for first-time pregnant women who are at least 37 weeks along, either going into labor on their own or being induced. It's not for those already fully dilated without oxytocin, have had children before, are expecting multiples, or whose babies have significant health issues.
What is being tested?
The study randomly assigns participants to either continue using oxytocin during the second stage of labor or stop it altogether. The goal is to see how stopping or continuing oxytocin affects labor complications.
What are the potential side effects?
Oxytocin may cause side effects like intense contractions leading to fetal distress, uterine rupture in rare cases, and postpartum hemorrhage due to uterine atony.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not on oxytocin when my cervix is fully dilated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during admission for delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and during admission for delivery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Second stage duration
Secondary study objectives
Estimated blood loss
Rate of Postpartum hemorrhage
Chorioamnionitis
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Discontinue OxytocinExperimental Treatment1 Intervention
Group II: Continue OxytocinActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
2,000 Previous Clinical Trials
2,343,862 Total Patients Enrolled
University of MichiganOTHER
1,863 Previous Clinical Trials
6,441,181 Total Patients Enrolled

Media Library

Oxytocin (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04303702 — N/A
Labor Complications Research Study Groups: Discontinue Oxytocin, Continue Oxytocin
Labor Complications Clinical Trial 2023: Oxytocin Highlights & Side Effects. Trial Name: NCT04303702 — N/A
Oxytocin (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04303702 — N/A
~117 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top